银屑病患者妊娠期和哺乳期的治疗进展  

Progress in the treatment of psoriasis during pregnancy and lactation

作　　者：蒋晓妍 刘克帅 高敏[2,3] 张晓艳 JIANG Xiao-yan;LIU Ke-shuai;GAO Min(Beijing University of Chinese Medicine,Beijing 100029,China)

机构地区：[1]北京中医药大学,100029 [2]中日友好医院皮肤病与性病科 [3]北京大学医学部

出　　处：《实用皮肤病学杂志》2022年第5期291-295,共5页Journal of Practical Dermatology

摘　　要：银屑病是一种免疫介导的慢性炎症性疾病,约2/3患者发病年龄接近育龄期,对妊娠期和哺乳期患者治疗时需要考虑到对胎儿或者婴儿的影响,所以可使用的药物十分有限。近年来,随着银屑病治疗药物的不断发展,处于妊娠期和哺乳期的银屑病患者暴露于药物的可能性增加,治疗银屑病用药时必须要考虑到母亲及胎儿的安全,这使得妊娠期及哺乳期的银屑病治疗成为一大挑战。该文将对妊娠期和哺乳期银屑病患者的治疗进展进行综述。Psoriasis is an immune-mediated chronic inflammatory diseasethat develops in approximately two-thirds of patients nearing their reproductive age.Due to the need to consider the impact on the fetus or infant when treating patients during pregnancy and lactation,the drugs available are very limited.In recent years,with the continuous development of psoriasis treatment drugs,patients with psoriasis during pregnancy and lactation are more likely to be exposed to drugs.The safety of the mother and fetus must be taken into consideration when using drugs to treat psoriasis.This makes the treatment of psoriasis during pregnancy and lactation a major challenge.This article will review the treatment progress of patients with psoriasis during pregnancy and lactation.

关 键 词：银屑病 妊娠期 哺乳期 传统治疗 生物制剂 

分 类 号：R758.63[医药卫生—皮肤病学与性病学]